The Priority Review

Tag

Reinovax Biologics Co., LTD

1 story

Stories

  1. Clinical trials

    Reinovax registers Phase 3 trial of PCV24 in adults

    The study plans to enroll 1260 Chinese adults aged 18 years and older to evaluate the safety and immunogenicity of the 24-valent pneumococcal conjugate vaccine PCV24. It plans to start on November 24, 2026, with primary completion in October 2027.